Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

A Surprise "Spark" For Pre-Cancerous Colon Polyps
Researchers at the Huntsman Cancer Institute (HCI) at the University of Utah studied the events leading to colon cancer and found that an unexpected protein serves as the "spark" that triggers formation of colon polyps, the precursors to cancerous tumors.
generic viagra online
Let's Get Moving For Heart Children's Health!
The Children"s Heart Federation (CHF) launches Let"s Get Moving for Heart Children"s Health: a call to action to include children with congenital heart disease in PE at school and to increase their access to sport in the community, at its House of Common"s reception today (14 May) in the presence of Gerry Sutcliffe MP, Minister for Sport and one hundred delegates, including representatives of nine leading sports development organisations. The event, which takes place during Children"s Heart Week (9-17 May), is designed to highlight the right of children and young people with congenital heart disease (CoHD) to sporting opportunities, in order to tackle the exclusion of pupils with CoHD from PE.
News of the day
New Taxes Could Help Pay For Reform, But Would Cost Political Capital
Two new taxes that could help pay for health care reform both carry political baggage. The first, a possible new tax on at least some employer-sponsored health benefits, has support from members of Congress on both sides of the aisle. But during last year"s presidential campaign, President Obama spoke out strongly against just such a plan when his opponent, Sen. John McCain suggested it, Roll Call reports. "Within weeks, Obama may find himself hawking around the country legislation that includes a provision he so ardently rejected during the campaign. Obama didn"t just oppose the exclusion. He all but drew a "read my lips" line in the sand ... "For the first time in American history, [McCain] wants to tax your health benefits," Obama said on the campaign trail. "Apparently, Sen. McCain doesn"t think it"s enough that your health premiums have doubled"" (Koffler, 6/4).
Oncology

Positive Outcome Reached At 16 Weeks For Avexa's ATC Phase III Trial

Avexa Limited (ASX:AVX) announced that the Data Safety Monitoring Board (DSMB) met today to review the 16 week data from Avexa"s apricitabine (ATC) Phase III clinical trial. The DSMB reviewed the data and recommended continuation of the study with the 800mg dose. Patients taking the 1200mg dose will be transitioned to the optimum 800mg dose to continue their therapy. "We are delighted with the recommendation by the DSMB for the continuation of the Phase III trial," said Dr Julian Chick, Avexa"s Chief Executive Officer. "The 800mg dose is considerably easier to formulate into fixed dose combinations, thus increasing the commercial potential for ATC. Given ATC"s excellent safety and activity profile, these results allow us to move forward with increased confidence in ATC as a treatment option for HIV patients." Avexa"s Phase III trial compares ATC to 3TC in drug-resistant HIV patients. The 16 Week component had three arms comparing doses of ATC at 800mg and 1200mg to the 3TC control arm. A minimum of 50 patients were enrolled in each arm. In all three arms, patients received either ATC or 3TC as part of an optimized background regimen. The trial will continue with two arms comparing the 800mg ATC dose to 3TC. The Phase III trial is being conducted with more than 130 sites worldwide. Patients from the earlier Phase IIb study, which used the 800mg ATC dose, have been successfully treated with ATC for up to three years. This provides further evidence of the safety, efficacy, and durability of 800mg ATC for the treatment of HIV. About apricitabine (ATC) Apricitabine (ATC) is an anti-HIV nucleoside reverse transcriptase inhibitor. ATC is Avexa"s lead program and has successfully completed the 96 week dosing of its Phase IIb clinical trial and commenced its Phase III trials worldwide in January 2008 in HIV patients with NRTI resistance. In clinical trials to date, ATC has shown the following characteristics: a unique resistance profile over 96 weeks of treatment, continued efficacy beyond two years of treatment, an excellent safety profile, and an ongoing immunological benefit. Dr Jonathan Coates, Avexa"s Chief Scientific Officer, is a former Project Leader for multiple anti-viral programs at GlaxoSmithKline and a co-inventor of anti-viral drug 3TC, one of the best selling anti-HIV drugs in history with over USD $8 billion in global sales to date. ATC targets a current unmet medical need that has earned the compound Fast Track status with the U.S. Food and Drug Administration. About the Data Safety Monitoring Board (DSMB) The Data Safety Monitoring Board (DSMB) for Avexa is a group of international experts that reviews, on a regular basis, accumulating data from ATC"s ongoing Phase 3 clinical trial. The DSMB advises Avexa regarding the continuing safety of trial subjects, as well as the continuing validity and scientific merit of the trial. Avexa Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009